48 Weeks Combination Therapy for Patients With HBeAg-negative Chronic Hepatitis B Virus (HBV) Infection
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate whether in patients with chronic HBeAg-negative
hepatitis B, PEG-IFN-ribavirin combination therapy for 1 year leads to enhanced response (HBV
DNA <10E4 copies/ml and normal ALT 24 weeks after treatment discontinuation) in comparison
with pegylated interferon (PEG-IFN) monotherapy.